A Study to Evaluate Treatment of Delayed Sleep-Wake Phase Syndrome with Melatonin in Patients with Comorbid Alcohol Use Disorders

Overview

About this study

The purposes of this study are to demonstrate the feasibility of assessing delayed dim light melatonin onset (DLMO) in patients with comorbid AUD and DSWPD utilizing a combination of questionnaires and laboratory assay of salivary melatonin levels, and to examine the impact of low-dose melatonin on SOL and overall sleep quality in patients withcomorbid AUD and DSWPD with delayed DLMO compared to those without delayed DLMO.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Subjects 18 years or older.
  • Admitted to the IAP with a primary diagnosis of moderate-severe AUD.

Exclusion Criteria:

  • Currently on melatonin or other hypnotic medication.
  • Unable or unwilling to provide informed consent.
  • Pregnant or considering pregnancy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bhanuprakash Kolla, M.D.

Contact us for the latest status

Contact information:

Cynthia Stoppel CCRP

(507)284-5914

Stoppel.Cynthia@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20471252

Mayo Clinic Footer